This Stock Is Up 704% in 2025 But Has No Products to Its Name

Relmada Therapeutics (RLMD) is a clinical-stage pharma company with no commercialized products and a $141 million market cap. RLMD has shown strong technical momentum, gaining 440% since August. Shares have a 100% “Buy” technical opinion from Barchart. Despite technical strength, RLMD lacks revenue, faces pipeline setbacks, and is rated “Hold” on Wall Street. Author’s Note: Investments are judged by revenue, earnings, cash flow, and dividends – that’s Investing 101. This company was founded in 200 ...